At the end of October 2013, Sanofi’s R&D pipeline contains 52 projects (excluding Life Cycle Management) and vaccine candidates in clinical development of which 12 are in Phase III or have been submitted to the health authorities for approval.
All projects in late phases of development
All projects in early phases of clinical development
Clostridium Difficile : the hope to prevent a major nosocomial infection
"Cdiffense", the clinical phase III program for Sanofi Pasteur’s vaccine against Clostridium difficile, begins in August 2013. This vaccine will ultimately help prevent one of the leading causes of infection in hospitals.
Genzyme R&D portfolio